The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Prognostic value of CRM1in pancreas cancer
Open accessAbstract
Purpose: Pancreatic cancer is a highly aggressive malignant tumour with poor prognosis. The median survival is only 6 months. This study investigated the prognostic value of nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 (CRM1) expression in pancreas cancer. Methods: CRM1 expression was detected, by Western blot, in pancreatic tissue from 69 cancer patients and 10 normal subjects. Results: CRM1 showed increased expression in pancreatic cancer tissue (P = 0.007). The high expression of CRM1 was associated with increased serum levels of CEA (P = 0.002) and CA19-9 (P = 0.005). There was an association between CRM1 expression and tumour size (P = 0.01), lymphadenopathy (P = 0.004) and liver metastasis (P = 0.003). High CRM1 expression was not correlated with the other clinicopathological parameters. High CRM1 expression was a prognostic indicator for progression-free survival (PFS) (P = 0.006) as well as overall survival (OS) (P = 0.001). Expression of CRM1 was an independent prognostic parameter for poorer PFS and OS (95% CI, 1.27–5.39). Conclusions: CRM1 expression demonstrated prognostic value in pancreatic cancer. Prospective studies are required to determine the prognostic role of high expression of CRM1 in pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738
DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma
Biankin, A. V., Morey, A. L., Lee, C.-S., Kench, J. G., Biankin, S. A., Hook, H. C., Head, D. R., Hugh, T. B., Sutherland, R. L., & Henshall, S. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.063 · Cited by 163 · cited 1×
“5,6 Numerous genetic (K‐ras, p16 and SMAD4 [7-9] and epigenetic alterations occur during the development of pancreatic adenocarcinoma.”
Background
Cited by
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Genomic and molecular characterization of esophageal squamous cell carcinoma
Lin, D.-C., Hao, J.-J., Nagata, Y., Xu, L., Shang, L., Meng, X., Sato, Y., Okuno, Y., Varela, A. M., Ding, L.-W., et al. (2014) · Nature Genetics · doi:10.1038/ng.2935 · Cited by 626
Nuclear export of proteins and drug resistance in cancer
Turner, J. G., Dawson, J., & Sullivan, D. M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.016 · Cited by 350
Tai, Y.-T., Landesman, Y., Acharya, C., Calle, Y., Zhong, M. Y., Cea, M., Tannenbaum, D., Cagnetta, A., Reagan, M., Munshi, A. A., et al. (2014) · Leukemia · doi:10.1038/leu.2013.115 · Cited by 308
Nucleo-cytoplasmic transport as a therapeutic target of cancer
Gravina, G. L., Senapedis, W., McCauley, D., Baloglu, E., Shacham, S., & Festuccia, C. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0085-1 · Cited by 275
Metadata
- Authors
- Huang, W.-Y., Yue, L., Qiu, W.-S., Wang, L.-W., Zhou, X.-H., & Sun, Y.-J.
- Venue
- Clinical and Investigative Medicine
- Published
- 2009-12-01
- Volume
- 32
- Issue
- 6
- Pages
- E315-E321
- ISSN
- 0147-958X (ISSN-L)
- 1488-2353
- OpenAlex
- W2156025284
- Cited by
- 170
- References
- 2
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.